Company profile: Adicet Bio
1.1 - Company Overview
Company description
- Provider of first-in-class allogeneic gamma delta CAR T cell therapies for cancer, including ADI-001 targeting B-cells for B cell-mediated autoimmune diseases and B-cell non-Hodgkin’s lymphoma; ADI-270 targeting CD70 for solid tumors such as renal cell carcinoma; and an armored PSMA CAR program for metastatic castration-resistant prostate cancer. Expanded access is currently not provided.
Products and services
- ADI-001: Investigational allogeneic gamma delta CAR T cell therapy that targets B-cells to treat B cell-mediated autoimmune diseases and B-cell non-Hodgkin’s lymphoma
- Armored PSMA CAR Gamma Delta T Cell Program: Gamma delta T cell CAR construct targeting PSMA with documented homing in metastatic castration-resistant prostate cancer, including armoring to address suppressive tumor microenvironment
- ADI-270: Armored CD70 CAR gamma delta T cell therapy targeting CD70 for potential treatment in solid tumors such as renal cell carcinoma
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Adicet Bio
Alexion
HQ: United States
Website
- Description: Provider of biologic therapies for severe, life-threatening diseases, including hematologic, kidney and neurologic conditions, transplant rejection, cancer and autoimmune disorders; portfolio includes SOLIRIS (PNH, aHUS, NMOSD), ULTOMIRIS (PNH, aHUS), STRENSIQ (HPP) and KANUMA (LAL-D), plus patient support and managed access programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alexion company profile →
ESBATech
HQ: Switzerland
Website
- Description: Provider of fully human antibody fragments for therapeutic applications, leveraging proprietary, fully human single-chain antibody frameworks to generate product candidates against clinically relevant targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ESBATech company profile →
Apeiron Biologics
HQ: Austria
Website
- Description: Provider of discovery and development of novel cancer immunotherapies, with products including Qarziba (cancer immunotherapy, licensed to EUSAPharma), APN401 (first-in-class autologous cell therapy inhibiting the immune checkpoint Cbl-b using RNAi to treat solid tumors), and APN01 (inhaled treatment in clinical trials targeting SARS-CoV-2 in the respiratory tract).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apeiron Biologics company profile →
Selexys Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutics under development for inflammatory and thrombotic diseases, targeting the underlying disease mechanism—adhesion of white blood cells to sites of inflammation mediated by P-selectin binding; privately held.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Selexys Pharmaceuticals company profile →
Vaccinogen
HQ: United States
Website
- Description: Provider of vaccines and other immunotherapeutic products for cancers and infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaccinogen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Adicet Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Adicet Bio
2.2 - Growth funds investing in similar companies to Adicet Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Adicet Bio
4.2 - Public trading comparable groups for Adicet Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →